I

Integra LifeSciences

Regenerative medicine, surgical devices provider

Clinical Scientist

Full-TimeUpdated on 10/4/2026
$82k - $113k+ Bonus + Commission + Equity + Other variable compensation
Mid
Master's, PhD
Princeton, NJ, USA
In Person

About the job

Requirements
  • A Master's degree or higher in Biomedical Engineering, Biomaterials, Tissue Engineering, Regenerative Medicine, Biological Sciences, Public Health, Epidemiology, Health Outcomes Research, or a related scientific discipline.
  • At least 3 years of relevant experience in clinical development, clinical research, medical affairs, epidemiology, health outcomes, real-world evidence, or related evidence-generation functions.
  • Strong analytical, critical-thinking, and scientific problem-solving skills.
  • Knowledge of clinical research methodology, study design, and evidence-generation principles.
  • Understanding of biostatistics and experience interpreting clinical, real-world, and published data.
  • Ability to apply scientific understanding of biomaterials, tissue remodeling, and regenerative mechanisms to clinical evidence generation, study design, data interpretation, and scientific communications.
  • Ability to synthesize complex clinical and scientific information into clear, actionable insights and recommendations.
  • Ability to conduct literature reviews, evidence gap assessments, scientific landscape analyses, and evidence synthesis activities.
  • Familiarity with real-world evidence, outcomes research, registry, claims-based, and health economics research methodologies.
  • Effective project management and organizational skills, with the ability to manage multiple priorities and deadlines.
  • Strong scientific writing skills to support publications, abstracts, study reports, and scientific presentations.
  • Experience working with clinical, real-world, registry, or claims data and utilizing analytical or data visualization tools such as Excel, R, SAS, SQL, Power BI, Tableau, or similar.
  • Ability and willingness to travel up to 20% of work time; travel may occasionally occur outside normal business hours, including weekends.
  • Ability to undertake the role's physical requirements, including repeatedly sitting, listening, speaking, and walking through airports.
  • Ability to follow safety precautions when exposed to potentially dangerous, hazardous, or biohazardous materials and to use personal protective equipment as frequently required.
Responsibilities
  • Contribute to the development and execution of clinical evidence strategies supporting products across the Tissue Reconstruction portfolio.
  • Conduct literature reviews, evidence gap assessments, and scientific landscape analyses to inform evidence-generation priorities.
  • Lead the scientific design of assigned studies and contribute to protocols, data collection instruments, analysis plans, and study reports in collaboration with Clinical Operations, Medical Communications, and Biostatistics.
  • Design, plan, and execute clinical studies, registries, real-world evidence, outcomes research, and claims-based research initiatives.
  • Lead assigned study and evidence-generation workstreams and be accountable for timelines, deliverables, study quality, and execution.
  • Analyze, interpret, and synthesize clinical, real-world, health economics, and published data to generate scientific insights regarding evidence gaps, competitive evidence evaluations, and landscape analyses to inform clinical development and evidence strategy.
  • Contribute to scientific publications, conference presentations, and other evidence dissemination activities.
  • Present scientific findings and evidence-based recommendations to internal stakeholders and cross-functional teams.
  • Collaborate with Medical Affairs, Regulatory Affairs, Clinical Operations, Biostatistics, R&D, Marketing, Market Access, and external investigators to align evidence-generation activities with product development and business needs.
  • Support investigator and key opinion leader collaborations through study planning discussions, advisory activities, and investigator-initiated research programs.
Desired Qualifications
  • Experience supporting clinical studies, registries, real-world evidence, outcomes research, health economics, or claims-based research projects.
  • Experience within the medical device or biotechnology industry.
  • Academic training, research experience, or scientific expertise in biomaterials, tissue engineering, regenerative medicine, wound healing, tissue repair, soft-tissue reconstruction, or related fields.
  • Experience developing scientific communications, including manuscripts, abstracts, posters, presentations, reports, or literature reviews.

About the company

Integra LifeSciences develops medical technologies for tissue repair and regeneration, including tissue-regeneration scaffolds, neurosurgical devices, wound care products, and specialized surgical instruments. Its scaffolds are implanted on wounds to provide a temporary matrix that guides new tissue growth and gradually integrates with the patient's tissue. The company differentiates itself through a diversified, multi-domain portfolio built via acquisitions, spanning regenerative medicine and conventional medical devices. Its goal is to broaden access to regenerative technology and raise standards of care in surgery and tissue repair.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Plainsboro Township, New Jersey

Founded

1989

Get referred to Integra LifeSciences

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q2 2026 revenue reached $391.9 million, with organic growth and raised EPS guidance.
  • S&P upgraded Integra to B on October 1, 2026, citing normalization progress.
  • Management targets $200 million operating cash flow in 2026, aided by cost savings.

What critics are saying

  • Cincinnati flooding cuts Q3 revenue $7 million and Q4 revenue $15 million to $20 million.
  • The Cincinnati plant returns only in Q2 2027, extending customer loss and backlog risk.
  • Boston cGMP securities litigation threatens damages, injunctions, and existential brand erosion.

What makes Integra LifeSciences unique

  • Integra spans neurosurgery, wound care, and reconstructive biologics, reducing single-product dependence.
  • Braintree's June 2026 ramp and Q4 2026 SurgiMend relaunch restore proprietary supply control.
  • 2027 Liberties launch and SurgiMend PMA target create new neurosurgery and breast-reconstruction wedges.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Medical Insurance

Dental Insurance

Vision Insurance

Short-Term Disability

Long-Term Disability

401(k) Retirement Plan

Growth & Insights and Company News

Headcount

6 month growth

↑ 4%

1 year growth

↑ 4%

2 year growth

↑ 4%
Associated Press
Oct 2nd, 2026
Integra LifeSciences cuts 2026 guidance after Cincinnati flooding disrupts production

Integra LifeSciences has lowered its full-year 2026 financial guidance following flooding at its Cincinnati manufacturing facility in July. The medical technology company now expects annual revenue of $1.634 billion to $1.654 billion, down from previous guidance of $1.654 billion to $1.695 billion. The flooding disrupted production of several products in the company's Specialty Surgical Technologies portfolio. Integra estimates the supply disruption reduced third quarter revenue by approximately $7 million and will impact fourth quarter revenue by $15 million to $20 million. The company expects third quarter revenue of $410 million to $412 million and adjusted earnings per share of $0.55 to $0.59. Full-year adjusted earnings per share guidance has been revised to $2.30 to $2.40, down from $2.40 to $2.50. Integra maintains property and business interruption insurance and expects recoveries to mitigate a substantial portion of the earnings impact. The facility is expected to return to full manufacturing operations during the second quarter of 2027.

MarketScreener
Oct 2nd, 2026
Integra LifeSciences Launches $600 Million Senior Secured Term Loan B

Integra LifeSciences said Friday that it has launched a $600 million seven-year senior secured term loan B as part of a broader refinancing transaction. The medical technology company said it...

Yahoo Finance
May 29th, 2026
Integra LifeSciences shares jump 6% after Citigroup upgrades rating and raises price target to $16

Integra LifeSciences shares rose 6.1% after Citigroup upgraded its rating from Sell to Neutral and raised its price target to $16 from $11. Analyst Joanne Wuensch's upgrade reflects reduced downside risk, though not yet a bullish outlook. The upgrade follows strong first-quarter 2026 results reported 22 days earlier, when the stock gained 5.3%. Integra's revenue grew 2.4% year-on-year to $391.9 million, beating estimates, whilst adjusted earnings per share of $0.54 exceeded consensus by 32.8%. The company raised its full-year earnings guidance and appointed Stuart Essig as CEO. Integra shares are up 36.7% year-to-date and recently hit a 52-week high of $16.42, though five-year returns remain significantly negative.

Yahoo Finance
May 17th, 2026
Integra LifeSciences targets $200M operating cash flow as SurgiMend relaunch nears Q4

Integra LifeSciences reported first-quarter revenue and earnings per share above guidance, citing progress in its operational transformation efforts. Chief Financial Officer Lea Knight said internal indicators show fewer supply disruptions, better yields and improved cash flow. The company is maintaining its focus on neurosurgery, tissue reconstruction and ENT markets following a leadership change that saw Stuart return as chairman and CEO. Integra is preparing to relaunch SurgiMend in the fourth quarter after operationalising its Braintree manufacturing facility in June and rebuilding inventory in the third quarter. Management expects $25 million to $30 million in cost savings and is targeting approximately $200 million in operating cash flow and $140 million in free cash flow this year. The company also reported reduced tariff pressure, with full-year impacts now expected at $0.10 per share versus a prior estimate of $0.32.

Yahoo Finance
May 15th, 2026
Integra LifeSciences beats Q1 expectations, raises full-year EPS guidance to $2.45

Integra LifeSciences reported first-quarter results that beat Wall Street expectations, with revenue of $391.9 million and adjusted EPS of $0.54, surpassing estimates by 2.6% and 33.4%, respectively. The medical device company attributed the performance to stronger tissue reconstruction demand, improved supply execution and operational improvements. CEO Stuart Essig emphasised that quality remediation and operational work enabled more reliable product availability. CFO Lea Knight said increased gross margins were driven by favourable product mix, tariff benefits and reduced remediation costs. The company reaffirmed its full-year revenue guidance of $1.68 billion whilst raising adjusted EPS guidance to $2.45, a 4.3% increase. Operating margin improved to 10.4% from 8.2% year-on-year. Management indicated no plans for divestitures, focusing instead on current product mix and gradual market share recovery.